Company: PCRX
Filing Date: 2025-02-27
Form Type: 10-K
Source: 0001396814-25-000041
Chunk: 34

Company: Pacira BioSciences, Inc.
Filing Date: 2025-02-27
Form: 10-K
Item: Item 16
Chunk 34
---
 sales in the periods presented as follows (in thousands):Year Ended December 31,202420232022Net product sales:EXPAREL$548,962 $538,120 $536,899 ZILRETTA118,089 111,098 105,517 iovera°22,813 19,685 15,258 Bupivacaine liposome injectable suspension7,322 3,342 6,476 Total net product sales$697,186 $672,245 $664,150 

Pacira BioSciences, Inc.  |  2024 Annual Report on Form 10-K  |  Page F-18

Table of ContentsPACIRA BIOSCIENCES, INC.NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

NOTE 5—INVENTORIES

The components of inventories, net are as follows (in thousands): December 31, 20242023Raw materials$50,800 $54,099 Work-in-process27,384 31,215 Finished goods47,098 19,039   Total$125,282 $104,353 

NOTE 6—FIXED ASSETS 

Fixed assets, net, summarized by major category, consist of the following (in thousands): December 31, 20242023Machinery and equipment (1) (2)$160,643 $121,773 Leasehold improvements (2)86,034 61,826 Computer equipment and software (2)23,473 17,186 Office furniture and equipment1,952 2,543 Construction in progress (2)27,996 105,905 Total300,098 309,233 Less: accumulated depreciation (1)(132,929)(135,306)Fixed assets, net$167,169 $173,927 For information on useful lives by asset category, refer to Note 2, Summary of Significant Accounting Policies.(1) During the year ended December 31, 2024, the Company disposed of $19.0 million of fully depreciated machinery and equipment associated with its 45-liter EXPAREL manufacturing process at its contract manufacturing facility located in Swindon, U.K. The Company continues to operate its  enhanced, larger-scale EXPAREL manufacturing process at the same facility.(2) During the year ended December 31, 2024